IGM Biosciences (IGMS) Competitors $1.19 -0.08 (-6.30%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IGMS vs. CYRX, CMPS, OLMA, ARCT, AURA, ATAI, GLUE, SEPN, PVLA, and ATYRShould you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Cryoport (CYRX), COMPASS Pathways (CMPS), Olema Pharmaceuticals (OLMA), Arcturus Therapeutics (ARCT), Aura Biosciences (AURA), Atai Life Sciences (ATAI), Monte Rosa Therapeutics (GLUE), Septerna (SEPN), Palvella Therapeutics (PVLA), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. IGM Biosciences vs. Cryoport COMPASS Pathways Olema Pharmaceuticals Arcturus Therapeutics Aura Biosciences Atai Life Sciences Monte Rosa Therapeutics Septerna Palvella Therapeutics Atyr PHARMA Cryoport (NASDAQ:CYRX) and IGM Biosciences (NASDAQ:IGMS) are both small-cap transportation companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations. Which has more risk and volatility, CYRX or IGMS? Cryoport has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CYRX or IGMS? 92.9% of Cryoport shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 10.1% of Cryoport shares are owned by insiders. Comparatively, 57.0% of IGM Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor CYRX or IGMS? In the previous week, Cryoport had 8 more articles in the media than IGM Biosciences. MarketBeat recorded 8 mentions for Cryoport and 0 mentions for IGM Biosciences. IGM Biosciences' average media sentiment score of 1.23 beat Cryoport's score of 0.88 indicating that IGM Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Cryoport Positive IGM Biosciences Positive Do analysts recommend CYRX or IGMS? Cryoport presently has a consensus target price of $11.67, indicating a potential upside of 107.96%. IGM Biosciences has a consensus target price of $5.50, indicating a potential upside of 362.18%. Given IGM Biosciences' higher probable upside, analysts plainly believe IGM Biosciences is more favorable than Cryoport.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cryoport 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83IGM Biosciences 1 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.90 Is CYRX or IGMS more profitable? Cryoport has a net margin of -70.08% compared to IGM Biosciences' net margin of -7,534.03%. Cryoport's return on equity of -13.35% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cryoport-70.08% -13.35% -6.43% IGM Biosciences -7,534.03%-155.42%-61.04% Which has higher earnings & valuation, CYRX or IGMS? Cryoport has higher revenue and earnings than IGM Biosciences. Cryoport is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCryoport$228.39M1.23-$99.59M-$2.49-2.25IGM Biosciences$2.68M26.55-$246.42M-$3.24-0.37 Does the MarketBeat Community believe in CYRX or IGMS? Cryoport received 179 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 65.88% of users gave Cryoport an outperform vote while only 47.68% of users gave IGM Biosciences an outperform vote. CompanyUnderperformOutperformCryoportOutperform Votes25165.88% Underperform Votes13034.12% IGM BiosciencesOutperform Votes7247.68% Underperform Votes7952.32% SummaryCryoport beats IGM Biosciences on 13 of the 18 factors compared between the two stocks. Remove Ads Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IGMS vs. The Competition Export to ExcelMetricIGM BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.13M$6.25B$5.28B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.336.6921.6317.68Price / Sales26.55222.70371.0892.88Price / CashN/A65.6738.1534.64Price / Book0.345.776.373.94Net Income-$246.42M$142.01M$3.20B$247.45M7 Day Performance12.26%2.88%1.79%0.48%1 Month Performance-3.64%-13.93%-9.41%-7.08%1 Year Performance-87.07%-12.36%9.61%-0.35% IGM Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IGMSIGM Biosciences4.0546 of 5 stars$1.19-6.3%$5.50+362.2%-86.5%$71.13M$2.68M-0.33190Positive NewsCYRXCryoport2.6779 of 5 stars$5.66-1.9%$11.83+109.1%-67.0%$282.49M$228.39M-1.671,020Analyst ForecastGap DownCMPSCOMPASS Pathways2.5499 of 5 stars$3.02+6.0%$20.20+568.9%-63.7%$279.87MN/A-1.37120Positive NewsOLMAOlema Pharmaceuticals2.7836 of 5 stars$4.06+7.7%$27.67+581.4%-61.2%$277.43MN/A-1.8570Short Interest ↓Positive NewsGap DownARCTArcturus Therapeutics3.0636 of 5 stars$10.18+4.9%$59.20+481.5%-63.9%$276.08M$138.39M-4.59180Positive NewsGap DownAURAAura Biosciences1.9829 of 5 stars$5.45+2.8%$22.75+317.4%-26.2%$273.73MN/A-3.1550Short Interest ↑Gap DownATAIAtai Life Sciences2.9175 of 5 stars$1.38+7.0%$10.50+660.9%-32.9%$273.66M$308,000.00-1.7080Positive NewsGLUEMonte Rosa Therapeutics2.9737 of 5 stars$4.41+4.5%$15.50+251.5%-32.6%$271.26M$75.62M-2.4190Short Interest ↓Positive NewsGap DownSEPNSepterna2.0824 of 5 stars$6.07+6.1%$33.00+443.7%N/A$269.76M$1.08M0.00N/ANews CoverageGap DownPVLAPalvella Therapeutics3.621 of 5 stars$24.44+12.3%$44.43+81.8%N/A$269.30M$42.81M-2.02N/AAnalyst RevisionATYRAtyr PHARMA2.729 of 5 stars$3.01+1.3%$18.60+517.9%N/A$267.47M$235,000.00-3.2053Positive News Remove Ads Related Companies and Tools Related Companies CYRX Alternatives CMPS Alternatives OLMA Alternatives ARCT Alternatives AURA Alternatives ATAI Alternatives GLUE Alternatives SEPN Alternatives PVLA Alternatives ATYR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IGMS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IGMS Stock Free IGMS Stock Alerts